Study of NT 201 compared to placebo in adults with moderate to severe platysma prominence

3 1

What is this study about?

This study focuses on Platysma Prominence, a condition where neck bands become visibly prominent. The research evaluates a medication called NT 201 (also known as Bocouture), which contains Botulinum toxin type A, compared to placebo for treating moderate to severe cases of this condition. The platysma is a thin, flat muscle in the neck that can become more noticeable with age, causing visible vertical bands.

The purpose of this research is to determine how safe and effective NT 201 is when used as a treatment for people with moderate to severe platysma bands in the neck area. The study involves giving participants either the active medication or placebo through intramuscular injections. Some participants will receive the actual treatment while others will receive a placebo solution that looks identical to the real medication.

During the study, participants will receive treatments and have their neck appearance evaluated multiple times. The medication will be administered as an infusion solution directly into the platysma muscle. The maximum amount of medication that can be given in a single day is 96 units, with a total possible amount of 192 units over the entire treatment period, which lasts approximately 17 weeks.

1 Initial treatment

You will receive a single treatment of either NT 201 or placebo through intramuscular injection.

The placebo consists of sucrose and human serum albumin mixed with sterile saline.

The active medication contains botulinum neurotoxin type A without complexing proteins.

The treatment will be administered into your platysma muscles (neck muscles).

2 2-week assessment

After 2 weeks (Visit 4), your progress will be evaluated based on:

The doctor will assess the appearance of your neck muscles using a grading scale.

You will complete a self-assessment of your neck muscle appearance.

You will fill out a satisfaction questionnaire about the treatment results.

3 Follow-up period

The study continues with regular follow-up visits to monitor your progress.

The doctor will assess if you achieve either ‘none to minimal’ or ‘mild’ muscle prominence.

Your improvement will be measured as a change of at least 2 grades from your starting condition.

4 Repeat treatment

You may receive additional treatment during the study period.

The study is expected to continue until October 11, 2027.

Regular assessments will continue throughout the study period to monitor safety and effectiveness.

Who Can Join the Study?

  • Must be between 18 and 65 years old when agreeing to participate in the study
  • Must have four visible neck bands (two on each side of the neck – inner and outer platysma bands)
  • Must have either moderate or severe prominence of neck bands when contracting neck muscles, as evaluated by both the doctor and participant (evaluations may differ)
  • Must be bothered by the appearance of their neck and score at least 16 points on a special questionnaire about neck appearance concerns
  • For women participants:
    • Must not be pregnant or breastfeeding
    • Must either be unable to have children (for example, due to menopause), OR
    • If able to have children, must use approved birth control methods during the study
  • Both men and women can participate in the study if they meet all other requirements

Who Cannot Join the Study?

  • Age below 18 years or above 65 years
  • Previous treatment with botulinum toxin (a protein that temporarily relaxes muscles) in the neck area within the past 4 months
  • Known allergy or sensitivity to the study medication or its components
  • Pregnancy or breastfeeding
  • Active infection or inflammation in the treatment area
  • History of difficulty swallowing (dysphagia)
  • Neuromuscular junction disorders (conditions affecting nerve and muscle connections) such as myasthenia gravis
  • Use of medications that could interfere with neuromuscular function
  • Previous neck surgery or significant scarring in the treatment area
  • Any medical condition that could affect the safety of the participant or the study results
  • Current participation in other clinical trials or within 30 days before study start
  • Inability to follow study procedures or attend follow-up visits
  • History of drug or alcohol abuse within the past year

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Other Sites

Site Name City Country Status
Klinika Ambroziak Sp. z o.o. Warsaw Poland
Privatpraxis für Dermatologie und Ästhetik Dr. Tatjana Pavicic Munich Germany
Synexus Polska Sp. z o.o. Poznan Poland
Hamburg University Hamburg Germany
CentroDerm GmbH Wuppertal Germany
Clinical Research Group Sp. z o.o. Warsaw Poland
Bodokh Isaac Cannes France
Fachaerztliche Gemeinschaftspraxis fuer Dermatologie Und Venerologie Allergologie Umweltmedizin Lasermedizin GbR Blankenfelde-Mahlow Germany
Dr. Niesmann And Dr. Othlinghaus GbR Bochum Germany
Medicorium GmbH Friedrichsdorf Germany
Klinika Osipowicz & Turkowski Sp. z o.o. Warsaw Poland
Dorota Bystrzanowska „High-Med”. Przychodnia Specjalistyczna Warsaw Poland
Dermoklinika Centrum Medyczne s.c. M. Kierstan. J. Narbutt , A. Lesiak Lodz Poland
NZOZ Specjalistyczny Ośrodek Dermatologiczny DERMAL Adam Wroński Bialystok Poland
Dermedic Jacek Zdybski Ostrowiec Swietokrzyski Poland
Privatpraxis Dr. Hilton & Partner Duesseldorf Germany
Royalderm Agnieszka Nawrocka Warsaw Poland
Derma Science GmbH Hamburg Germany
Hhcn Hkmxt urw Lryqowpmjtyr Psuiben Potsdam Germany
Cbdpacbowxearyxss Nice France
Nhwqmsgupj Giry Kassel Germany
Inbtwlua Zgylvud Da Bqspbxxflxggicwik Oświęcim Poland
Tafdqjyc Sef z otjg Piotrkow Trybunalski Poland
Pxggbx fja Hdxitdmosywuqvh Dgt myfu Eza Ksqpxxlr Bap Drensteinfurt Germany
Zyioupy Mmi Szm z owjs Lublin Poland

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not recruiting
20.10.2025
Germany Germany
Not recruiting
20.10.2025
Poland Poland
Not recruiting
20.10.2025
Spain Spain
Not recruiting
20.10.2025

Trial locations

NT 201 is a medication being studied for treating moderate to severe platysma prominence (visible neck bands). It is a type of injectable treatment that targets the muscles in the neck area. The medication works by temporarily reducing muscle activity in the platysma, which are the muscles that cause visible bands in the neck.

Placebo is an inactive substance used as a comparison to measure the true effects of NT 201. It looks identical to the active treatment but contains no active ingredients.

Note: Both treatments are given as injections into the neck area where the muscle bands are visible.

Investigated Diseases:

Platysma Prominence – A cosmetic condition where the platysma muscles in the neck become more visible and pronounced, creating visible bands or cords. The platysma is a broad, thin sheet of muscle that extends from the chest and shoulder regions up to the jaw. When these muscles become more prominent with age or genetic predisposition, they can create visible vertical bands in the neck area, particularly noticeable during facial expressions or muscle tension. The condition can range from mild to severe, with more severe cases showing very distinct rope-like bands in the neck. This condition often becomes more noticeable as people age due to loss of skin elasticity and subcutaneous fat in the neck area.

Trial ID:
2025-520499-24-00
Protocol code:
NT-PPR-EU002
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Czechia Denmark France Germany Greece Italy +2
  • Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease

    Recruiting

    3 1
    Investigated Diseases:
    Belgium Czechia Denmark Finland France Germany +6